| Lucentis | A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | Phase 3 | Active not recruiting | 451 | Feb 4, 2027 |
| Afimkibart | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | Phase 3 | Active not recruiting | 400 | Jan 30, 2027 |
| Alectinib | A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Active not recruiting | 68 | Jan 19, 2027 |
| Pertuzumab | A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial | Phase 3 | Active not recruiting | 154 | Dec 31, 2026 |
| Atezolizumab | A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) | Phase 3 | Active not recruiting | 382 | Dec 31, 2026 |
| Afimkibart | Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease | Phase 2 | Active not recruiting | 21 | Dec 31, 2026 |
| Atezolizumab | A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer | Phase 2 | Active not recruiting | 204 | Dec 31, 2026 |
| Satralizumab | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis | Phase 3 | Active not recruiting | 122 | Dec 16, 2026 |
| RO7204239 | A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy | Phase 3 | Completed | 97 | Nov 2, 2026 |
| Glofitamab | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Completed | 211 | Oct 22, 2026 |
| Tobemstomig | A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer | Phase 2 | Completed | 83 | Oct 15, 2026 |
| Azacitidine | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | Phase 2 | Terminated | 36 | Oct 12, 2026 |
| Tobemstomig | A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma | Phase 2 | Completed | 199 | Oct 5, 2026 |
| Ascorbic acid | Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer | Phase 2 | Terminated | 3 | Sep 24, 2026 |
| Atezolizumab | A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer | Phase 2 | Completed | 32 | Sep 22, 2026 |
| Trastuzumab | Pre Operative Trastuzumab in Operable Breast Cancer | Phase 3 | Terminated | 1,100 | Sep 11, 2026 |
| trastuzumab emtansine | Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers | Phase 2 | Completed | 131 | Sep 4, 2026 |
| Lucentis | A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Phase 3 | Active not recruiting | 984 | Sep 2026 |
| Satralizumab | A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD) | Phase 2 | Active not recruiting | 30 | Aug 26, 2026 |
| Giredestrant | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | Phase 2 | Completed | 33 | Aug 25, 2026 |
| Lucentis | Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration | Phase 2 | Completed | 177 | Aug 25, 2026 |
| RO7204239 | A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity | Phase 2 | Active not recruiting | 285 | Aug 24, 2026 |
| Ascorbic Acid 1000 MG | Vitamin C Effectiveness in Preventing Urinary Tract Infections After Gynecological Surgeries | Phase 2 | Completed | 200 | Aug 15, 2026 |
| Crovalimab | Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Completed | 59 | Aug 13, 2026 |
| Alectinib | A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Completed | 11 | Jul 31, 2026 |
| trastuzumab emtansine | HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer | Phase 2 | Terminated | 87 | Jul 23, 2026 |
| Tiragolumab | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | Phase 3 | Completed | 760 | Jul 22, 2026 |
| Atezolizumab | A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | Phase 3 | Active not recruiting | 557 | Jun 30, 2026 |
| Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | Phase 2 | Active not recruiting | 69 | Jun 30, 2026 |
| Atezolizumab | An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) | Phase 3 | Active not recruiting | 49 | Jun 30, 2026 |
| Mosunetuzumab | A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma | Phase 3 | Active not recruiting | 478 | May 31, 2026 |
| Tominersen 60 mg | GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease | Phase 2 | Active not recruiting | 301 | May 31, 2026 |
| Atezolizumab | Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer | Phase 2 | Completed | 32 | May 30, 2026 |
| Enicepatide | A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus | Phase 2 | Completed | 447 | May 29, 2026 |
| Azacitidine | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Phase 2 | Terminated | 34 | May 29, 2026 |
| Lucentis | A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia | Phase 3 | Completed | 280 | May 22, 2026 |
| RO7446603 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema | Phase 2 | Completed | 388 | May 19, 2026 |
| Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) | Phase 2 | Active not recruiting | 534 | May 14, 2026 |
| Risdiplam | A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy | Phase 2 | Completed | 11 | May 4, 2026 |
| XL092 | Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer | Phase 3 | Active not recruiting | 901 | May 2026 |